loader image
Thursday, May 22, 2025
86.9 F
McAllen
We Welcome your Press Release
- Advertisement -

Long-acting Antibody Treatment vs. Omicron Variant in Patients with Compromised Immune System

Translate to Spanish or other 102 languages!

DHR Health Institute for Research and Development is currently offering long-acting monoclonal antibody treatment to PREVENT COVID-19 in high-risk patients. Image for illustration purposes.
DHR Health Institute for Research and Development is currently offering long-acting monoclonal antibody treatment to PREVENT COVID-19 in high-risk patients. Image for illustration purposes.

Mega Doctor News

- Advertisement -

EDINBURG, TX – DHR Health Institute for Research and Development is currently offering long-acting monoclonal antibody treatment to PREVENT COVID-19 in high-risk patients. This is the only treatment currently available to prevent infection by the Omicron variant of SARS-CoV-2…the virus that causes COVID-19.

On December 8, 2021, the U.S. Food and Drug Administration issued an Emergency Use Authorization allowing the use of AstraZeneca’s long-acting antibody EVUSHELDTM to be used for prevention of COVID-19 in subjects 12 years and older with moderate to severe immunocompromised status before exposure to the virus.

“The majority of the patients who are currently hospitalized with severe COVID-19 are those who are unvaccinated, and those who are vaccinated, but have a compromised immune system” said Sohail Rao, MD, MA, DPhil, President and CEO, DHR Health Institute for Research & Development. “Given that Omicron is the dominant variant which is responsible for the current spike in COVID-19 cases in the US and globally, EVUSHELDTM is the only antibody that can offer long-term protection against this variant in patients with weakened immune system”

- Advertisement -

I

Long-acting Antibody Treatment vs. Omicron Variant in Patients with Compromised Immune SystemTreatment with this long-acting antibody will provide patients with protection against SARS-CoV-2 (including its Omicron variant) for up to 6-9 months. In the last few weeks, we have treated over 50 patients at DHR Health with this monoclonal antibody with a very satisfactory outcome.

If you or your patient is interested to receive this treatment or need to discuss their condition further, please call 956-342-4896 or download the contact information by using this QR Code: 

- Advertisement -
- Advertisement -

- Advertisement -

More Articles

Physical Activity Linked with Improved Cancer Survival, New ACS Study Finds

Mega Doctor News By American Cancer Society (ACS)  Newswise — A new large analysis led...

The Importance of Reducing Melanoma Risks

Mega Doctor News By West Virginia University Newswise — As warmer weather beckons everyone outdoors,...

DHR Health’s Bariatric Institute Hosts Uplifting Patient Reunion and Fashion Show

Mega Doctor News By Roberto Hugo Gonzalez On May 21, 2025, the DHR...

Prostate Cancer: Your Questions Answered

Mega Doctor News Cedars Sinai Former President Joe Biden’s announcement that he has...
- Advertisement -
×